Articles

• Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
• Atezolizumab Shows Durable Response, Tolerability in Urothelial Carcinoma

Atezolizumab injection (Tecentriq) has been approved by the US Food and Drug Administration for patients with locally advanced or metastatic urothelial carcinoma with disease progression after or ≤12 months of receiving platinum-containing chemotherapy. The recommended dosage of the drug, which is programmed death-ligand 1 blocking antibody, is 1200 mg administered intravenously every 3 weeks until disease progression or unacceptable toxicity.

The US Food and Drug Administration has approved nivolumab (Opdivo) for patients with classical Hodgkin Lymphoma that has progressed or relapsed following autologous hematopoietic stem cell transplantation and post-transplant brentuximab vedotin, according to an announcement by the agency. Notably, the intravenous drug was granted accelerated approval, and Breakthrough Therapy Designation.

Lenvatinib capsules (Lenvima) have been approved in combination with everolimus in patients with advanced renal cell carcinoma who have had 1 previous anti-angiogenic therapy, according to an announcement by the US Food and Drug Administration. The combination has demonstrated greater progression-free and overall survival rates, compared with lenvatinib monotherapy.

You pay more than your fair share of taxes, so when it comes to your investments, why would you pay more than you absolutely have to? While it may be too late to save taxes on investments you made last year, it’s the perfect time to focus on saving money this year, so we want to share some tax tactics to keep your tax bill for 2016 in check.

The job of the oncology medical team is to put out the fire, stop the emergency, and save the patient’s life.

Patients with acute myeloid leukemia (AML) often feel blindsided by their diagnosis, have trouble understanding their treatment choices, and suffer symptoms that are inadequately addressed. This is a patient population with sizable, and unmet, palliative care and psychosocial needs.

Scottsdale, AZ—Therapeutic, low-level laser therapy (LLLT) reduces pain and accelerates the resolution of oral mucositis (OM) in patients with head and neck cancer receiving chemoradiotherapy (CRT), according to Eric Allan, MD.

Scottsdale, AZ—The superoxide dismutase mimetic GC4419 markedly reduced the incidence, intensity, and duration of severe oral mucositis in a study of patients with head and neck cancer.